CHMP January 2026 Approvals: Expanding Access t...

By João L. Carapinha

February 2, 2026

CHMP January 2026 Approvals Signal Expanded Access to Innovative Therapies The
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
Innovations in Haematology Cell Therapy at ASH 2025
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leuka...
Accelerating Access to Latin America Innovative Therapies Through Collaborati...
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset